An imbalance in gene activity in two types of immune cells explains why lung fibrosis after a severe COVID-19 infection doesn ...

A recent study revealed that early-life exposure to tobacco significantly elevates the risk of developing idiopathic ...

Celldex Therapeutics , Inc. (NASDAQ:CLDX), a biopharmaceutical company focused on developing innovative therapies for ...

FY25 saw AdAlta (ASX:1AD) focus on increasing its corporate muscle, with two new board members and additional advisors engaged.

NEW HAVEN, Conn., Jan. 30, 2025 /PRNewswire/ -- (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the ...

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal lung disease characterized by the scarring (fibrosis) of lung tissue, ...

STOCKHOLM, SE / ACCESS Newswire / January 29, 2025 / Vicore Pharma Holding (STO:VICO)Stockholm, January 29, 2025 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of ...

The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...

Discover the connection between genetic risk factors for idiopathic pulmonary fibrosis and the development of post-COVID-19 ...

Columnist Sam Kirton says that at his age, and as someone with pulmonary fibrosis, he's had much experience dealing with grief.

EGEIRO Pharma (ISIN Code: BE0974387194 - Mnemonic: ALVET), a biopharmaceutical company specializing in the repositioning and reformulation of existing drugs, in particular for Idiopathic Pulmonary ...

Rein Therapeutics (NASDAQ:RNTX) received a Buy rating from Rodman & Renshaw, with a newly established price target of $8.00. The firm began its coverage of the biotech company, highlighting its focus ...